What drove the after-hours spike in 2181.HK stock?

The jump came on heavy volume and news-sensitive buying tied to Mabpharm’s clinical pipeline. Market participants cited Phase III programmes and upcoming earnings on 26 Mar 2026. High flow and speculative positioning amplified the move in Hong Kong's HKSE trading session.

Is 2181.HK stock overvalued compared with peers?

On standard metrics Mabpharm looks expensive: price-to-sales **6.00** and price-to-book **25.74** versus healthcare sector averages. Negative EPS and high debt-to-equity **3.09** add valuation risk versus larger biotech peers.

What is Meyka AI’s short-term forecast for 2181.HK stock?

Meyka AI's forecast model projects a monthly price of **HK$0.75**, implying about **+4.17%** from **HK$0.72**. This model-based projection is not a guarantee and depends on pipeline news and market conditions.

How should investors approach 2181.HK stock after this move?

Use event-driven sizing and strict stop losses. Short-term traders can ride momentum but watch overbought signals. Longer-term investors should wait for clearer clinical outcomes and improved fundamentals before increasing exposure.

HK Stocks

2181.HK Mabpharm (HKSE) rises 41.18% after hours: monitor Phase III catalysts

ByHuzaifa Zahoor March 16, 2026March 16, 2026

The 2181.HK stock surged in after-hours trading on 16 Mar 2026, closing at HK$0.72, up 41.18% on heavy volume of 8,094,000 shares. We view the move as a market reaction to clinical and sector dynamics in Hong Kong’s biotech patch. Trading volume ran roughly 39x the average, signalling strong speculative interest. This note summarises drivers, valuation, technicals, risks and a model-based forecast for Mabpharm Limited (2181.HK) on the HKSE.